Episode 39 — how NGS is transforming cancer care through precision medicine, and what still stands in the way: insurance coverage gaps, clinical workflow friction, and the slow march from test availability to test adoption.

TPM Podcast #46 — liquid biopsy, multi-omics, and AI are reshaping personalized care, but the diagnostics business model still hinders the field. A conversation about what it will take to make these technologies accessible at scale.

A live(ish) conversation recorded at AGBT 2025 — covering the state of play in next-generation sequencing: where the market stands, what the conference signaled, and what comes next for the tools and diagnostics layer of genomics.

A conversation with Theral Timpson about how recent economic pressures have exposed fundamental flaws in the life science tools business model — and why the foundational pricing assumptions in the sector need to be rethought from the ground up.

A conversation with Hamid Ghanadan (CEO, The Linus Group) on where actionable near-term opportunities lie for life science tools and diagnostics companies — combining market intelligence with a practitioner's view of the current science landscape.

A live webinar for the BioTools Innovator 2022 accelerator cohort walking through frameworks for selecting a beachhead market — aimed at early-stage life science tools and diagnostics companies.

The fourth installment in the BioTools Innovator expert webinar series — covering sales and marketing strategy for life science tools and diagnostics companies at the early commercial stage.

Lack of diversity in clinical trials and genomic databases doesn't just create health disparities — it creates blind spots that limit the commercial reach of precision medicine. The case for inclusion as both an ethical imperative and a market-expansion strategy.

Why the beachhead strategy — winning a narrow application first before expanding — is the right model for life science tools and diagnostics companies trying to disrupt entrenched incumbents.

A practitioner's take on how to make the consulting case interview process more thoughtful, equitable, and effective — improving both candidate experience and the quality of hiring decisions.

Digital biomarkers — measuring health signals through devices and software rather than blood draws — represent the real promise that Theranos obscured. The case for a category that is maturing quietly and building on more solid scientific ground.

Why diagnostic technologies — not just therapeutics — will define the precision medicine era. The infrastructure that makes precision care possible is systematically undervalued.

A first-person account of going through whole-genome sequencing and what it reveals — both scientifically and personally — about the promise and limitations of genomic medicine at the consumer level.

An early forecast that the NGS clinical sequencing market would surpass $1 billion by 2015 — identifying oncology and prenatal testing as the largest opportunities, and FDA clearance and payer reimbursement as the key inflection points for widespread adoption.